bioMérieux S.A./€BIM
06:30
10:10
13:45
17:25
21:00
1D1W1MYTD1Y5YMAX
About bioMérieux S.A.
bioMérieux S.A. is a French company specialized in the field of in vitro diagnostics, operating within the healthcare industry. The company develops, manufactures, and markets diagnostic solutions that are primarily used for detecting disease-causing microorganisms. These solutions include a broad range of products, such as diagnostic tests for infectious diseases, cancer, and cardiovascular diseases, as well as industrial microbiological controls. Founded in 1963 by Alain Mérieux, bioMérieux is headquartered in Marcy-l'Étoile, near Lyon, France. The company has a global presence, serving clients around the world through a network of subsidiaries and distributors. Its competitive strength lies in its extensive product portfolio and commitment to research and development, enabling it to address evolving medical and industrial testing needs.
Ticker
€BIM
Sector
Primary listing
PAR
Employees
14,451
Headquarters
Website
bioMérieux S.A. Metrics
BasicAdvanced
€13B
33.79
€3.17
0.46
€0.90
0.84%
Price and volume
Market cap
€13B
Beta
0.46
52-week high
€142.00
52-week low
€95.19
Average daily volume
22K
Dividend rate
€0.90
Financial strength
Current ratio
2.266
Quick ratio
1.297
Long term debt to equity
8.489
Total debt to equity
12.86
Interest coverage (TTM)
31.42%
Profitability
EBITDA (TTM)
999.5
Gross margin (TTM)
56.27%
Net profit margin (TTM)
9.17%
Operating margin (TTM)
17.08%
Effective tax rate (TTM)
27.18%
Revenue per employee (TTM)
€290,000
Management effectiveness
Return on assets (TTM)
8.23%
Return on equity (TTM)
9.49%
Valuation
Price to earnings (TTM)
33.786
Price to revenue (TTM)
3.07
Price to book
3.2
Price to tangible book (TTM)
4.5
Price to free cash flow (TTM)
28.794
Free cash flow yield (TTM)
3.47%
Free cash flow per share (TTM)
3.72
Dividend yield (TTM)
0.84%
Forward dividend yield
0.84%
Growth
Revenue change (TTM)
8.28%
Earnings per share change (TTM)
-8.61%
3-year revenue growth (CAGR)
6.01%
10-year revenue growth (CAGR)
8.34%
3-year earnings per share growth (CAGR)
-12.06%
10-year earnings per share growth (CAGR)
10.06%
3-year dividend per share growth (CAGR)
1.92%
10-year dividend per share growth (CAGR)
10.44%
Bulls say / Bears say
bioMérieux posted 9.4% organic sales growth in H1 2025, with strong double-digit gains in core GO•28 segments and a 12% rise for BIOFIRE respiratory panels, showing resilient demand.
Free cash flow surged to €170 million in H1 2025—more than triple the prior period—boosting liquidity and the ability to invest in strategy.
Management reiterated its goal for full-year CEBIT growth of 12–18% for 2025, showing confidence in continued margin gains from GO•28 operational efficiencies.
bioMérieux lowered its 2025 sales growth forecast to 5.5–6.5% from the previous 6–7.5% due to a delayed respiratory season, signaling exposure to shifts in disease trends.
Net income for the first half of 2025 dropped 25% to €161 million after a €146 million impairment on Vitek Reveal technology, casting doubt on returns from R&D investments.
Organic growth in Q3 slowed to 3% as the company faced double-digit declines in microbiology sales in China and an 8% decrease in BIOFIRE respiratory panels, exposing risks from geographic and product concentration.
Data summarised monthly by Lightyear AI. Last updated on 9 Nov 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for bioMérieux S.A. stock?
bioMérieux S.A. (BIM) has a market cap of €13B as of November 11, 2025.
What is the P/E ratio for bioMérieux S.A. stock?
The price to earnings (P/E) ratio for bioMérieux S.A. (BIM) stock is 33.79 as of November 11, 2025.
Does bioMérieux S.A. stock pay dividends?
Yes, the bioMérieux S.A. (BIM) stock pays dividends to shareholders. As of November 11, 2025, the dividend rate is €0.9 and the yield is 0.84%. bioMérieux S.A. has a payout ratio of 0% on a trailing twelve-month basis.
When is the next bioMérieux S.A. dividend payment date?
The next bioMérieux S.A. (BIM) dividend payment date is unconfirmed.
What is the beta indicator for bioMérieux S.A.?
bioMérieux S.A. (BIM) has a beta rating of 0.46. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.